Weigela

by | Mar 13, 2018 | Weigela

How Can We Help?
You are here:
< Back

Fosdevirine is an experimental antiviral agent of the non-nucleoside reverse transcriptase inhibitor class that was studied for potential use in the treatment of HIV-AIDS.[1][2]

It was discovered by Idenix Pharmaceuticals and was being developed by GlaxoSmithKline and ViiV Healthcare, but it has now been discontinued[3][4] due to unexpected side effects.[5]

References

  1. ^ Dousson C, Alexandre FR, Amador A, Bonaric S, Bot S, Caillet C, et al. (March 2016). "Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor". Journal of Medicinal Chemistry. 59 (5): 1891–8. doi:10.1021/acs.jmedchem.5b01430. PMID 26804933.
  2. ^ "Fosdevirine". AIDSinfo. U.S. National Library of Medicine, U.S. Department of Health and Human Services. Archived from the original on 2019-08-11. Retrieved 2018-08-14.
  3. ^ "Fosdevirine". Adis Insight. Springer Nature Switzerland AG. Highest Development Phases: Discontinued, HIV-1 infections
  4. ^ "Fosdevirine". MedKoo Biosciences. GSK2248761 is no longer in clinical development.
  5. ^ Margolis DA, Eron JJ, DeJesus E, White S, Wannamaker P, Stancil B, Johnson M (2013). "Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761)". Antiviral Therapy. 19 (1): 69–78. doi:10.3851/IMP2689. PMID 24158593. S2CID 6147197.
Categories
Table of Contents